Related Experiment Video
Updated: Aug 20, 2025
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment
Ignacio Barriuso1,2,3, Fernando Worner1, Gemma Vilahur2,4
1Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida, 25198 Lleida, Spain.
Insights
New antithrombotic therapies aim to prevent blood clots in ischemic heart disease and stroke while reducing bleeding risks. This review explores current limitations and emerging treatments for better patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Ischemic cardiovascular diseases cause high global mortality.
- Antithrombotic therapy is crucial but carries bleeding risks.
- Understanding thrombus formation drives new drug development.
Purpose of the Study:
- Review limitations of current antithrombotic treatments.
- Provide an overview of emerging anticoagulant and antiplatelet agents.
- Highlight agents with potential to improve clinical outcomes in ischemic conditions.
Main Methods:
- Literature review of current antithrombotic therapies.
- Analysis of pathophysiology of thrombus formation.
- Survey of novel anticoagulant and antiplatelet agents in development.
Main Results:
- Current antithrombotics have significant bleeding risks.
- New agents target thrombus stabilization and growth.
- Emerging therapies aim to preserve hemostasis.
Conclusions:
- Novel antithrombotic agents show promise in improving outcomes.
- Balancing efficacy and safety remains a key challenge.
- Further research is needed for clinical translation.
Abstract:
Ischemic cardiovascular diseases have a high incidence and high mortality worldwide. Therapeutic advances in the last decades have reduced cardiovascular mortality, with antithrombotic therapy being the cornerstone of medical treatment. Yet, currently used antithrombotic agents carry an inherent risk of bleeding associated with adverse cardiovascular outcomes and mortality. Advances in understanding the pathophysiology of thrombus formation have led to the discovery of new targets and the development of new anticoagulants and antiplatelet agents aimed at preventing thrombus stabilization and growth while preserving hemostasis. In the following review, we will comment on the key limitation of the currently used antithrombotic regimes in ischemic heart disease and ischemic stroke and provide an in-depth and state-of-the-art overview of the emerging anticoagulant and antiplatelet agents in the pipeline with the potential to improve clinical outcomes.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Atherosclerosis III: Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins